Correlative study on neuro-endocrine differentiation and presence of somatostatin receptors in breast carcinomas

Abstract

To correlate the expression of neuro-endocrine (NE) markers with the presence of somatostatin receptors (SSR) in human breast cancer, a series of 100 cases was stained with the Grimelius silver procedure, by immunocytochemistry with specific NE markers (i.e., chromogranin A and B and synaptophysin) and by autoradiography for SSR.

Nine cases were positive for at least one NE marker, while 4 cases were positive for all of them. SSR were detected in 17 cases, either with low (10 cases) or with high receptor density (7 cases).

A highly significant correlation was established between the expression of NE markers and high SSR density.

Our findings are additional evidence of the existence of a group of breast cancers showing morphological and cytochemical similarity with neuro-endocrine tumors present in other organs.

The identification of this type of breast cancer is of biological and potential therapeutic interest.

 

 

About this publication.

 

See also:

- Somatostatin in oncology, the overlooked evidences;

- The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature;

- Pancreatic Adenocarcinoma: clinical records on 17 patients treated with Di Bella's Method;

- The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer;

- Oesophageal squamocellular carcinoma: a complete and objective response;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonisn, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma.